Methotrexate Orion

Methotrexate, the active ingredient in Methotrexate Orion, is an antimetabolite (folate antagonist) presented as a sterile injectable solution for intramuscular and subcutaneous administration. It is prescribed to manage autoimmune disorders such as rheumatoid arthritis and psoriasis, as well as to treat certain hematologic and solid‑tumor cancers in adult patients.

GNH USA supplies Methotrexate Orion as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, clinics and pharmacies worldwide, providing reliable cold‑chain logistics and regulatory support for cross‑border global procurement.

Methotrexate is used in several disease categories, primarily targeting immune‑mediated conditions and specific cancers.

- Rheumatoid arthritis: reduces joint inflammation and slows disease progression. - Psoriasis: decreases skin cell proliferation and improves plaque severity. - Acute lymphoblastic leukemia: interferes with malignant cell replication to achieve remission. - Non‑Hodgkin lymphoma: suppresses tumor growth as part of combination chemotherapy. - Breast cancer: used in high‑dose regimens to inhibit tumor cell division.

Methotrexate may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea and vomiting - Fatigue or weakness - Mouth ulcers or sore throat - Elevated liver enzymes

Serious or Rare Side Effects: - Severe liver toxicity or hepatitis - Pulmonary fibrosis or interstitial pneumonitis - Life‑threatening infection due to bone‑marrow suppression

When prescribing methotrexate, clinicians should observe several safety precautions to minimize toxicity. - Monitor liver function: perform baseline and periodic liver enzyme tests. - Monitor blood counts: check complete blood count regularly for cytopenias. - Avoid use in pregnancy: contraindicated due to teratogenic risk. - Adjust dose in renal impairment: reduce dosage or increase interval as needed. - Counsel on folic acid supplementation: recommended to reduce mucosal toxicity. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Methotrexate interacts with several medicines that can alter its efficacy or increase toxicity.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): can increase methotrexate serum levels and risk renal toxicity. - Proton pump inhibitors (e.g., omeprazole): may reduce renal clearance and raise toxicity risk.

Moderate Interactions (Monitor Closely): - Trimethoprim‑sulfamethoxazole: may enhance bone‑marrow suppression. - Live vaccines: increased risk of infection; avoid concurrent use. - Certain antibiotics (e.g., penicillins): may affect renal excretion.